e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Tuberculosis: epidemiology and public health management III
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk factors for anti-TB drug resistance in Poland
M. Korzeniewska-Kosela (Warsaw, Poland)
Source:
Annual Congress 2013 –Tuberculosis: epidemiology and public health management III
Session:
Tuberculosis: epidemiology and public health management III
Session type:
Thematic Poster Session
Number:
4464
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Korzeniewska-Kosela (Warsaw, Poland). Risk factors for anti-TB drug resistance in Poland. Eur Respir J 2013; 42: Suppl. 57, 4464
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
Risk factors for tuberculosis relapse in Polish patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Risk factors for acquired drug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Trends of MBT drug resistance
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia
Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease
Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Dynamics of primary multidrug drug resistance in Novokuznetsk over 10 years period
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
Risk factor and resistance pattern of MDR TB among suspected cases of Oromia Region
Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children
Year: 2015
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Trend and risk factors of drug resistance tuberculosis between 2005-2012 in Istanbul, Turkey
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
MDR TB treatment results of GFATM program implementation in Tomsk, Russia
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Drug resistance among new TB cases in some Russian regions
Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children
Year: 2015
Impact of drug injection using on TB-AIDS treatment outcomes
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
Failure predictors when treating MDR-TB
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Nationwide anti-tuberculosis drug resistance survey in the Republic of Azerbaijan
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation
Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1
Year: 2014
Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept